Trophoblast-Targeted Nanomedicine Modulates Placental sFLT1 for Preeclampsia Treatment

Lei Li1,2,3, Huijun Yang3,4, Pengzheng Chen1, Tao Xin5, Qian Zhou1,2, Dan Wei1, Yanan Zhang2 and Shan Wang1,2*

1 Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China, 2 Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, 3 Key Laboratory of Birth Regulation and Control Technology of National Health and Family Planning Commission of China, Jinan, China, 4 Maternal and Child Health Care of Shandong Province, Jinan, China, 5 Department of Neurosurgery, The First Affiliated Hospital of Shandong First Medical University, Jinan, China

The overexpressed soluble fms-like tyrosine kinase 1 (sFLT-1) in placenta is considered to be a potential therapeutic target for preeclampsia (PE). How to achieve efficient intervention of sFLT1 expression in the placenta is an urgent problem to be solved. PEG-PLA nanoparticle generated by double-emulsion methods is a novel siRNA delivery system. Synthetic placental CSA binding peptide (P-CSA-BP) is effective for targeting lipid-polymer nanoparticle to the placenta. We conjugated P-CSA-BP to the surface of PEG-PLA nanoparticle to create a novel placenta specific sFLT1 siRNA delivery system for the therapy of PE. Nanoparticles were synthesized using double emulsion method and characterized by dynamic light scattering and transmission electron microscopy (TEM). RT-PCR was employed to evaluate mRNA level and protein level was analyzed by ELISA kit. The tissue distribution of nanoparticles was observed through ex vivo images. The concentrations of nanoparticles in organs were measured using high-performance liquid chromatography. T-NPsisFLT1 had higher efficiency than NPsisFLT1 in accumulating in HTR-8/SVneo cells and significantly decreased the expression of sFLT1. Intravenously administered T-NPsisFLT1 specifically accumulated in placentas of mice. sFLT1 mRNA level in placenta and protein level in serum were declined by T-NPsisFLT1. T-NPsisFLT1 shown no obvious toxic effect on both mother and fetus. The utility of T-NPsisFLT1 nanoparticles as a sFLT1 siRNA placenta specific delivery system significantly silenced sFLT1 in mice and is safe for both mother and fetus. This nanoparticle is a novel potential therapeutic strategy for PE.

Keywords: nanoparticles, placental CSA binding peptide, sFLT1, preeclampsia, therapeutic strategy

INTRODUCTION

Preeclampsia is a special type of hypertensive disorders complicating pregnancy (HDCP) which is characterized by hypertension, proteinuria, hematological complications, and uteroplacental dysfunction (von Dadelszen and Magee, 2014). The fetal development is also significantly influenced by the pathogenesis of PE, such as amniotic fluid reduction, oxygenation defect, and...
growth restriction (Douglas and Redman, 1994). During the pathogenesis of PE, the dysfunction in maternal vascular system and the abnormal activation of maternal-fetal immune system are proved to be the two main factors (Lareasgoiti-Servitje, 2013). The worldwide prevalence of PE in all pregnant women is from 3 to 8% and nearly 18% maternal deaths are caused by PE based on its high maternal morbidity and mortality (Anderson et al., 2012). The primary prevention of PE is mainly performed through the treatment of aspirin, vitamin D, and low-dose calcium (Henderson et al., 2014). The termination of pregnancy or fetus delivery is thought to be the only definitive treatment for PE (World Health Organization [WHO], 2011). Although there has been great progress in the study of PE, the prediction and prevention of PE development is still a big challenge.

PE is proved to be an anti-angiogenic state. Soluble fms-like tyrosine kinase 1 (sFLT-1) is a shorter form of FLT-1 which lacks the intra-cytoplasmic and transmembrane domain and thus can circulates freely in maternal circulation (Salahuddin et al., 2007). The ability of binding with vascular endothelial growth factor (VEGF) and placental growth factor (PIGF) makes sFLT-1 to be the decoy receptor of these two factors in the maternal circulation (Rana et al., 2012). The sFLT1:PIGF ratio is proved to fluctuate during the normal pregnant. sFLT1 stays at a stable level till week 29–30 and then increases to a peak at week 40 (Palm et al., 2011). Meanwhile, The sFLT1:PIGF ratio decreases in week 9–12, stays at a low level from week 19–20 to 37–38, and then increases in week 39–40 (Palm et al., 2011). The tightly regulated sFLT1:PIGF ratio during pregnant is crucial for both placenta and fetal development. The elevated sFLT-1 level is observed in patients with PE (Levine et al., 2004). The pathogenesis of PE triggers the increasing of sFLT1 level in maternal circulation (Herraiz et al., 2018). The up-regulated sFLT-1 level in the maternal circulation decrease the levels of VEGF and PIGF and generates the endothelial dysfunction (Levine et al., 2006). It has been reported that sFLT-1 expression is up-regulated in the placenta and generated by villous and extravillous trophoblasts (Ahmad and Ahmed, 2004). Therefore, the overexpressed sFLT1 in placenta is considered to be a potential therapeutic target for PE. How to achieve efficient intervention of sFLT1 expression in the placenta is an urgent problem to be solved.

In recent, it has been proved that the systemically delivered sFLT1 siRNAs which are cholesterol conjugated and full chemical stabilized can accumulate in placentas, inhibit the expression of sFLT1, and alleviate proteinuria and hypertension (Turanov et al., 2012). Intra-amniotic injection of sFLT-1 plasmid DNA induced the inhibition of sFLT-1 and relieved the symptoms of PE in pregnant rats (Li et al., 2015). However, the systemic delivery of sFLT1 siRNAs may lack the intra-cytoplasmic and transmembrane domain and thus lacks the specific localization in the placenta syncytiotrophoblasts. Therefore, the major problem in the systemic delivery of sFLT1 siRNAs is the low specificity in the placenta epithelial cells.

In this research, we aimed to illustrate the effects of this method in placenta targeting and silencing of sFLT1 and analyze the toxic effect.

### MATERIALS AND METHODS

#### Animals

Pregnant CD1 mice were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). Mice were caged in pathogen-free animal room with 12 h light/12 h dark cycle. The gestation of mice was determined by checking vaginal plugs formation (E0.5 = vaginal plug day). At 14 and 15 days of gestation, the mice were treated by siRNA, NP-siRNA, or T-NP-siRNA through intravenous injection in the tail vein at the siRNA dosage of 2 mg/kg. The accumulation of Cy5-labeled siFLT1 in mice placenta was observed through ex vivo images. Placenta tissue samples and blood samples were collected for further investigation. The procedures of animal experiments in this research were approved by the Shandong Provincial Hospital Affiliated to Shandong University.

#### Cell Culture

HTR-8/SVneo cell lines were obtained from the American Type Culture Collection (ATCC, VA, United States). RPMI-1640 medium (Gibco, New York, United States) with 10% fetal bovine serum (FBS) (Gibco) and 1% penicillin/streptomycin (Sigma, St. Louis, United States) was applied for the cell culture under the standard conditions.

#### Preparation and Characterization of Nanoparticles

Lipid-polymer nanoparticles loaded with sFLT1 siRNAs (NP-siFLT1) were synthesized from carboxyl-polyethylene glycol-poly(D,L-lactide) (COOH-PEG8K-PLA8K), cationic lipid DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride), and sFLT1 siRNAs using double emulsion method which was previously published in other research (Xu et al., 2016). Synthetic placental CSA-binding peptides (P-CSA-BP) were conjugated to NP-siFLT1 to generate the trophoblast-targeted nanoparticles (T-NP-siFLT1) based on the method from other study (Zhang et al., 2018).

Size distribution and zeta potential of nanoparticles were measured through dynamic light scattering (DLS) in triplicate with the help of Zetasizer Nano ZS (Malvern, United Kingdom). The morphology of nanoparticles was visualized through transmission electron microscopy (TEM) (JEOL-2010 microscopy, Tokyo, Japan). The colloidal stability was investigated by incubating in phosphate buffered saline (PBS) with 10% fetal bovine serum (FBS) and analyzing the size of nanoparticles.

#### Gel Retardation Assay

The integrity of nanoparticles after 7 days’ incubation in PBS with 10% BSA was investigated by gel retardation assay. Naked siRNA was used as a control. Samples were mixed with gel loading buffer containing 1% SDS and separated by 2% agarose gel electrophoresis. The integrity of nanoparticles was determined by calculating the ratio of the retardation of siRNA in nanoparticles to that in naked siRNA. This ratio provides a quantitative measure of the protection of siRNA by the nanoparticles against degradation.

#### Gel Electrophoresis

The retardation of siRNA in nanoparticles was determined by gel electrophoresis. Samples were mixed with gel loading buffer containing 1% SDS and separated by 2% agarose gel electrophoresis. The integrity of nanoparticles was determined by calculating the ratio of the retardation of siRNA in nanoparticles to that in naked siRNA. This ratio provides a quantitative measure of the protection of siRNA by the nanoparticles against degradation.
gel electrophoresis. The samples in gel were observed by ethidium bromide staining.

**Immunohistochemistry**
Immunohistochemistry was employed to evaluate CSA expression in placenta tissues. After being deparaffinized and rehydrated, slides were treated by antigen retrieval buffer. Then the tissue sections were incubated with BSA for 1 h at room temperature. Then the sections were incubated with mouse monoclonal anti-chondroitin sulfate antibody (Abcam, Cambridge, United Kingdom) or control IgG (Abcam) at 4°C overnight. After being washed, the sections were incubated with HRP-donkey anti-mouse IgG (ThermoFisher, Waltham, United States). The sections were observed under a light microscope.

**Immunofluorescence**
Cells were fixed by 4% paraformaldehyde for 30 min at room temperature and permeabilized by 0.05% Triton X-100 for 10 min. After being blocked by 5% BSA for 1 h at room temperature, cells were incubated with anti-chondroitin sulfate antibody (Abcam) at 4°C overnight. After being washed by PBS for three times, the cells were incubated with anti-mouse IgG FITC antibody (Abcam) for 1 h at room temperature. Cell nucleus were stained with DAPI. Cells were observed by confocal microscope.

**Flow Cytometry**
5 × 10⁴ HTR-8/SVneo cells were planted in each well of a 24-well plate. After 24 h, cells were incubated with free Cy5 labeled siRNA (Cy5-siRNA), NP<sub>COOH-PEG</sub>-sRNA, or T-NP<sub>COOH-PEG</sub>-sRNA (100 nM) for 4 h. After incubation, cells were collected and analyzed by FACSCalibur (BD Biosciences, Bedford, United States). Mean fluorescence intensity of Cy5 was calculated by FlowJo 7.6.1 software.

**ELISA**
Fms-like tyrosine kinase 1 protein levels in cell medium or serum were evaluated by ELISA kit (R&D Systems, Minneapolis, United States) based on the manufacturer's instructions. Experiments were done in duplicate, and the protein levels were calculated using a standard curve. The activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum of mice were analyzed by colorimetric assay kits (Sigma, St. Louis, United States). Mean fluorescence intensity of Cy5 was calculated using a standard curve. The activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum of mice were analyzed by colorimetric assay kits (Sigma, St. Louis, United States). Mean fluorescence intensity of Cy5 was calculated using a standard curve. The activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum of mice were analyzed by colorimetric assay kits (Sigma, St. Louis, United States). Mean fluorescence intensity of Cy5 was calculated using a standard curve. The activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum of mice were analyzed by colorimetric assay kits (Sigma, St. Louis, United States). Mean fluorescence intensity of Cy5 was calculated using a standard curve.

**Statistical Analysis**
Statistical analysis was performed by GraphPad PRISM 6.0 software. Data were presented as mean ± SD. Student's t-test, one or two-way ANOVA analysis with a post hoc test were used to calculate the differences. Statistical analysis was significant when P value < 0.05.

**RESULTS**

**The Preparation and Characterization of Trophoblast-Targeted sFLT1 siRNA-Encapsulated Nanoparticles**
As shown in Figure 1A, NP<sub>sFLT1</sub> was constructed from COOH-PEG<sub>5K</sub>-PLA<sub>9K</sub>, DOTAP, and sisFLT1 through double emulsion method and T-NP<sub>sFLT1</sub> was fabricated by conjugating P-CSA-BP to the surface of NP<sub>sFLT1</sub>. DLS results shown that the resulted nanoparticles T-NP<sub>sFLT1</sub> had a relative larger particle size than NP<sub>sFLT1</sub> (Figure 1B). The conjugation of P-CSA-BP enlarged the size of the nanoparticle. The morphology of these two nanoparticles was checked by TEM and the representative TEM images were shown in Figure 1C. The P-CSA-BP could be observed on the surface of T-NP<sub>sFLT1</sub>. Both of the nanoparticles had slightly positive zeta potentials (Figure 1D). The incubation of siRNA-encapsulated nanoparticles in PBS demonstrated the colloidal stability of these two nanoparticles (Figure 1E). Based on the success of agarose gel retardation assay, no significant siRNA release was observed, indicating that both nanoparticles were successfully protected the encapsulated siRNA (Figure 1F). So, nanoparticles T-NP<sub>sFLT1</sub> was successfully generated from NP<sub>sFLT1</sub> and was proved to be stable.

Human sFLT-1 R: TACTGTCCCGAGATTGCGGTTT
Human β-actin F: CTGTGTCCTGCGGCC
Human β-actin R: AGCCTGGCCTTTGCG
Mouse sFlt-1 F: CGACTCACTATAGGAGACCC
Mouse sFlt-1 R: TGGCCCTGGCTGATGTTGCTGG
Mouse GAPDH F: GTGGCAAAATGGAATTTGGTGC
Mouse GAPDH R: GATGATGCCCGTTTGGC

**High-Performance Liquid Chromatography (HPLC)**
High-performance liquid chromatography was employed to evaluate the amount of sisFLT1 accumulated in different tissues. Tissues were harvested 1 day after injection. The performance of HPLC was based on the standard method (Zhang et al., 2018). One day after injection, relative tissues were collected and homogenized in PBS. 10% perchloric acid was added into the mixture and vortexed for 3 min. After being centrifuged at 14,000 × g for 20 min, supernatants were collected and filtered (0.45 µm). Mobile phase was composed of 40 mM potassium phosphate dibasic and acetonitrile. Flow rate was 1.0 mL/min. Ultraviolet absorbance at 313 nm was detected.

**Flow Cytometry**
5 × 10⁴ HTR-8/SVneo cells were planted in each well of a 24-well plate. After 24 h, cells were incubated with free Cy5 labeled siRNA (Cy5-siRNA), NP<sub>COOH-PEG</sub>-sRNA, or T-NP<sub>COOH-PEG</sub>-sRNA (100 nM) for 4 h. After incubation, cells were collected and analyzed by FACSCalibur (BD Biosciences, Bedford, United States). Mean fluorescence intensity of Cy5 was calculated using a standard curve.

**Statistical Analysis**
Statistical analysis was performed by GraphPad PRISM 6.0 software. Data were presented as mean ± SD. Student's t-test, one or two-way ANOVA analysis with a post hoc test were used to calculate the differences. Statistical analysis was significant when P value < 0.05.

**RESULTS**

**The Preparation and Characterization of Trophoblast-Targeted sFLT1 siRNA-Encapsulated Nanoparticles**
As shown in Figure 1A, NP<sub>sFLT1</sub> was constructed from COOH-PEG<sub>5K</sub>-PLA<sub>9K</sub>, DOTAP, and sisFLT1 through double emulsion method and T-NP<sub>sFLT1</sub> was fabricated by conjugating P-CSA-BP to the surface of NP<sub>sFLT1</sub>. DLS results shown that the resulted nanoparticles T-NP<sub>sFLT1</sub> had a relative larger particle size than NP<sub>sFLT1</sub> (Figure 1B). The conjugation of P-CSA-BP enlarged the size of the nanoparticle. The morphology of these two nanoparticles was checked by TEM and the representative TEM images were shown in Figure 1C. The P-CSA-BP could be observed on the surface of T-NP<sub>sFLT1</sub>. Both of the nanoparticles had slightly positive zeta potentials (Figure 1D). The incubation of siRNA-encapsulated nanoparticles in PBS demonstrated the colloidal stability of these two nanoparticles (Figure 1E). Based on the success of agarose gel retardation assay, no significant siRNA release was observed, indicating that both nanoparticles were successfully protected the encapsulated siRNA (Figure 1F). So, nanoparticles T-NP<sub>sFLT1</sub> was successfully generated from NP<sub>sFLT1</sub> and was proved to be stable.

Human sFLT-1 R: TACTGTCCCGAGATTGCGGTTT
Human β-actin F: CTGTGTCCTGCGGCC
Human β-actin R: AGCCTGGCCTTTGCG
Mouse sFlt-1 F: CGACTCACTATAGGAGACCC
Mouse sFlt-1 R: TGGCCCTGGCTGATGTTGCTGG
Mouse GAPDH F: GTGGCAAAATGGAATTTGGTGC
Mouse GAPDH R: GATGATGCCCGTTTGGC

**High-Performance Liquid Chromatography (HPLC)**
High-performance liquid chromatography was employed to evaluate the amount of sisFLT1 accumulated in different tissues. Tissues were harvested 1 day after injection. The performance of HPLC was based on the standard method (Zhang et al., 2018). One day after injection, relative tissues were collected and homogenized in PBS. 10% perchloric acid was added into the mixture and vortexed for 3 min. After being centrifuged at 14,000 × g for 20 min, supernatants were collected and filtered (0.45 µm). Mobile phase was composed of 40 mM potassium phosphate dibasic and acetonitrile. Flow rate was 1.0 mL/min. Ultraviolet absorbance at 313 nm was detected.

**Statistical Analysis**
Statistical analysis was performed by GraphPad PRISM 6.0 software. Data were presented as mean ± SD. Student's t-test, one or two-way ANOVA analysis with a post hoc test were used to calculate the differences. Statistical analysis was significant when P value < 0.05.

**RESULTS**

**The Preparation and Characterization of Trophoblast-Targeted sFLT1 siRNA-Encapsulated Nanoparticles**
As shown in Figure 1A, NP<sub>sFLT1</sub> was constructed from COOH-PEG<sub>5K</sub>-PLA<sub>9K</sub>, DOTAP, and sisFLT1 through double emulsion method and T-NP<sub>sFLT1</sub> was fabricated by conjugating P-CSA-BP to the surface of NP<sub>sFLT1</sub>. DLS results shown that the resulted nanoparticles T-NP<sub>sFLT1</sub> had a relative larger particle size than NP<sub>sFLT1</sub> (Figure 1B). The conjugation of P-CSA-BP enlarged the size of the nanoparticle. The morphology of these two nanoparticles was checked by TEM and the representative TEM images were shown in Figure 1C. The P-CSA-BP could be observed on the surface of T-NP<sub>sFLT1</sub>. Both of the nanoparticles had slightly positive zeta potentials (Figure 1D). The incubation of siRNA-encapsulated nanoparticles in PBS demonstrated the colloidal stability of these two nanoparticles (Figure 1E). Based on the success of agarose gel retardation assay, no significant siRNA release was observed, indicating that both nanoparticles were successfully protected the encapsulated siRNA (Figure 1F). So, nanoparticles T-NP<sub>sFLT1</sub> was successfully generated from NP<sub>sFLT1</sub> and was proved to be stable.

Human sFLT-1 R: TACTGTCCCGAGATTGCGGTTT
Human β-actin F: CTGTGTCCTGCGGCC
Human β-actin R: AGCCTGGCCTTTGCG
Mouse sFlt-1 F: CGACTCACTATAGGAGACCC
Mouse sFlt-1 R: TGGCCCTGGCTGATGTTGCTGG
Mouse GAPDH F: GTGGCAAAATGGAATTTGGTGC
Mouse GAPDH R: GATGATGCCCGTTTGGC
FIGURE 1 | Preparation of trophoblast-targeted nanoparticles encapsulating sFLT1 siRNA. (A) Nanoparticles loaded with sFLT1 siRNA (denoted as NP_sFLT1) was constructed from COOH-PEG5K-PLA8K, cationic lipid DOTAP, and sisFLT1 using double emulsion method. Trophoblast-targeted nanoparticles (denoted as T-NP_sFLT1) was fabricated by conjugating peptides, which could specific bind with CSA on the trophoblasts, to the surface of NP_sFLT1. (B) Size distributions of NP_sFLT1 and T-NP_sFLT1 were examined by DLS. (C) Representative TEM images of NP_sFLT1 and T-NP_sFLT1. Scale bars = 100 nm. (D) Zeta potential of nanoparticles examined via DLS. (E) Effect of incubation in PBS on the particle size. (F) Gel retardation assay for examining the integrity of nanoparticles 7-day post construction.

T-NP_sisFLT1 Specifically Target Trophoblast Cells in vitro

Chondroitin sulfate A is a protein which is proved to exist on the surface of placental syncytiotrophoblasts. Through the immunohistochemistry, we proved the expression of CSA in the tissue of mouse placenta (Figure 2A). HTR-8/SVneo cells were human trophoblast cells and the expression of CSA was observed through immunofluorescence (Figure 2B). To investigate the uptake of these two kinds of nanoparticles into HTR-8/SVneo cells, siRNA was labeled with Cy5 and cells were analyzed by flow cytometry after incubating with nanoparticles. Based on the result of flow cytometry, trophoblast cells incubated with T-NP_Cy5-siRNA had a significantly higher Cy5 signal intensity than those incubated with NP_Cy5-siRNA (Figures 2C,D). Furthermore, the internalized NP_Cy5-siRNA and T-NP_Cy5-siRNA in HTR-8/SVneo cells were observed by confocal microscopy (Figure 2E). These results indicated that T-NP_sisRNA had a higher efficiency than NP_sisRNA in targeting to trophoblast cells in vitro.

T-NP_sisFLT1 Inhibit the Expression of sFLT1 in vitro

To demonstrate the function of these two sFLT1 siRNA-encapsulated nanoparticles in the inhibition of sFLT1 expression in vitro, HTR-8/SVneo cells were treated with free si_sFLT1, NP_sisFLT1 or T-NP_sisFLT1 for 48 h. The mRNA levels of sFLT1 in cells were evaluated through RT-PCR and the results were shown in Figure 3A. When compared with cells treated by NP_sisFLT1, those cells treated by T-NP_sisFLT1 shown a significant
lower sFLT1 mRNA level and this phenomenon was enhanced by the increasing dosage. The protein level of sFLT1 was evaluated by ELISA and shown the same tendency with mRNA (Figure 3B). The protein levels of sFLT1 in HTR-8/SVneo cells were not altered by the treatment of nanoparticles encapsulating nonsense siRNA (NPsiNC and T-NPsiNC) (Figure 3C). T-NPsisFLT1 had a higher efficiency than NPsiFLTI in the inhibition of sFLT1 expression in trophoblast cells in vitro.

T-NPsisFLT1 Selectively Accumulate in Placenta and Downregulate sFLT1 Expression in Mice

The function of T-NPsisFLT1 was further checked in mouse model. Experimental design for testing accumulation ability of T-NP_Cy5-siRNA in pregnant CD1 mice was shown in Figure 4A. To illustrate the accumulation of the nanoparticles, pregnant CD1 mice were intravenously injected with NP_Cy5-siRNA and T-NP_Cy5-siRNA. Based on the ex vivo examination, the localization of T-NP_Cy5-siRNA in placenta was much higher than NP_Cy5-siRNA (Figure 4B). HPLC was employed to quantitatively compare the accumulation of the nanoparticles in different organs. As shown in Figure 4C, the amount of Cy5-siRNA in the placenta of mice treated by T-NP_Cy5-siRNA was significantly higher than in the placenta of mice treated by NP_Cy5-siRNA. But the distribution of Cy5-siRNA shown no significant differences in other organs. So, P-CSA-BP on the surface of T-NPsisFLT1 enhanced the nanoparticle’s specific accumulation ability in mice placenta. Experimental design for testing silencing ability of T-NPsisFLT1 in pregnant CD1 mice was shown in Figure 4D. We examined the mRNA levels of sFLT1 in the placenta of mice treated by different nanoparticles through RT-PCR. When compared with NPsisFLT1, the treatment of T-NPsisFLT1 significantly decreased the mRNA level of sFLT1 in the placenta of mice (Figure 4E). Circulating sFLT1 levels in mice were evaluated by ELISA and shown the same tendency (Figure 4F). So, P-CSA-BP on the surface of T-NPsisFLT1 also enhanced the nanoparticle’s sFLT1 silencing ability in mice placenta. It was proved that T-NPsisFLT1
had a higher efficiency than NP_{sFLT1} in accumulation in the placenta of mice and silencing sFLT1.

**Conjugating P-CSA-BP to the Surface of NP_{sFLT1} Does Not Enhance the Toxic Effect**

We further investigated whether conjugating P-CSA-BP to the surface of NP_{sFLT1} enhanced the nanoparticle’s toxic effect in mice. The changes of ALT and AST were widely used for illustrating the severity of the toxic effect on liver. The levels of the maternal liver transaminases ALT and AST in mice was analyzed after treatment. The normal ALT and AST levels indicated that the treatment of NP_{sFLT1} or T-NP_{sFLT1} had no obvious adverse effects (Figures 5A,B). We also checked the influence of these nanoparticles on the fetus. Both newborn pup number and weight were not influenced by the treatment of NP_{sFLT1} or T-NP_{sFLT1} (Figures 5C,D). Both of these two nanoparticles had low maternal and fetal toxic effect. Thus, conjugating P-CSA-BP to the surface of NP_{sFLT1} did not enhance the nanoparticle’s toxic effect in mice.

**DISCUSSION**

Based on previous research, the pathogenesis of PE can be divided into two different stages (Redman and Sargent, 2009). The first stage is asymptomatic, but abnormal placenta formation and accumulation of placenta released factors in maternal circulation can be observed. The symptomatic second stage is characterized by placental oxidative stress, hypertension and proteinuria, that eventually result in angioplasia in brain which caused eclampsia (Hladunewich et al., 2007). Since the molecular mechanism during the pathogenesis of PE is not fully understand, PE still lacks reliable method for prediction and diagnosis and effective therapeutic strategy (Ahmed et al., 2017). Untreated PE is life threatening and will develops into eclampsia with several severe complications (Arulkumaran and Lightstone, 2013). Till now, the only effective therapy for PE is the early delivery of the pregnancy.

In recent years, the pathogenesis of PE is proved to have a strong correlation with the factors generated and released from placenta (Levine et al., 2004). Several different researches have demonstrated the abnormal increased level of anti-angiogenic molecule sFLT-1 in the circulation of women with PE (He et al., 1999; Maynard et al., 2003). The accumulation of sFLT-1 has a strong correlation with the generation of hypertension through its function in antagonizing VEGF and PlGF (Fan et al., 2014). The sFLT-1/PlGF ratio is reported to be useful for the diagnosis and prognosis assessment of PE (Herraiz et al., 2018). sFLT-1 is also considered as a potential PE therapeutic target. Thadhani et al. (2016), have proved that apheresis therapy is efficient in removing sFLT-1 in the circulation of women with PE and extends the pregnancies with no obvious adverse effects on both mother and fetus. Brownfoot et al. (2016), demonstrated that metformin inhibits the production of sFLT-1 in villous trophoblast and prevents the pathogenesis of PE. In both mouse and baboon PE model, systemically delivered modified sFLT1 siRNAs accumulate in placentas, inhibit sFLT1 expression, and alleviate hypertension and proteinuria (Turanov et al., 2018). RNAi-based placental sFLT1 expression modulation is proved to be a novel therapeutic approach for PE. However, several limitations still exist in the development of this therapeutic strategy, such as siRNA degradation and difficulty in crossing cell membrane (Liu et al., 2014).

Nanoparticles can act as delivery system and have several benefits, including enhanced permeability, retention effect, and extravasation ability and are widely used in the therapy of cancer and other disease (Cheng et al., 2015). The transfer ability of nanoparticles to different organs is critical for the therapy. It is reported that molecular shape, surface modification, and particle size determine whether the nanoparticle can cross the placenta barrier (Muoth et al., 2016). Poly-amidoamine (PAMAM) dendrimers are shown to be excellent nanocarrier for...
siRNA delivery and siRNA-sFLT1-PAMAM complex is proved to be effective in inhibition sFLT1 expression and improving pregnancy outcomes in PE rat model (Yu et al., 2017). PEG-PLA nanoparticle generated by double-emulsion methods is a novel siRNA delivery system which is proved in both in vivo and in vitro cancer models (Yang et al., 2011). We aimed to use this PEG-PLA nanoparticulate system for the delivery of sFLT1 siRNA into placenta and inhibiting the pathogenesis of PE.

Despite the placenta is unrestricted exposed to drugs in maternal circulation, only a small proportion of non-targeted nanoparticles are successfully transported into placenta (Zhang et al., 2018). Thus, specific targeting the nanoparticles to placental tissues is critical for the development of nanoparticle-based therapeutic strategy for pregnancy-related disorders. CSA is a protein which exist on placental syncytiotrophoblasts. We confirmed the existence of CAS in both mice placenta tissues

**FIGURE 4** T-NP_sFLT1 selectively accumulate in placenta and downregulate sFLT1 expression. (A) Experimental design for in vivo testing of T-NP_sRNA accumulation in pregnant CD1 mice. Pregnant CD1 mice treated with T-NP encapsulating Cy5-labeled sisFL2T1 at 14 days of gestation, and the injection dosage of Cy5-sisFL2T1 was 2 mg/kg. The biodistribution of T-NP_Cy5-sRNA was qualitatively and quantitively detected 1 day later. (B) Ex vivo images of placenta in the pregnant mice after Cy5-labeled siRNA injection at 15 days of gestation. (C) Amount of Cy5 accumulated in indicated tissues 1 day after injection using HPLC. (D) Experimental design for in vivo silencing of sFLT1 via NP_sFL2T1. Pregnant CD1 mice were intravenously injected with 2 mg/kg of sisFL2T1 on pregnancy days 14 and 15 days of gestation, and killed for examination on allowed to deliver pups on 19 days of gestation or allowed to delivery. Blood was collected on the indicated days. (E) sFLT1 mRNA expression in placenta on 19 days of gestation examined via RT-PCR (n = 8 biologically independent animals). Data was shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.
FIGURE 5 | Toxic effect analysis of T-NP<sub>si</sub>sFLT1. Enzyme activities of ALT (A) and AST (B) at day 19 of gestation in mice injected with free si<sub>sFLT1</sub>, NP<sub>si</sub>sFLT1 or T-NP<sub>si</sub>sFLT1 (n = 8 biologically independent animals). Newborn pup number (C) and weights (D) from mice injected with free si<sub>sFLT1</sub>, NP<sub>si</sub>sFLT1 or T-NP<sub>si</sub>sFLT1 (n = 8 biologically independent animals). ns. no significant difference.

and human trophoblast HTR-8/SVneo cells. Synthetic placental CSA-binding peptide can specifically bind to trophoblasts in placenta but not to other cells expressing CSA in other tissues. It is reported that P-CSA-BP-conjugated nanoparticles is effective in targeting to the placenta and is a novel placenta-specific drug delivery option (Zhang et al., 2018). Based on the PEG-PLA nanoparticle system, we synthesized P-CSA-BP-conjugated PEG-PLA nanoparticles encapsulating sFLT1 siRNA and analyzed its function both in vivo and in vitro. Conjugating P-CSA-BP enlarged the particle size and decreased the surface potential of PEG-PLA nanoparticles. Both NP<sub>si</sub>sFLT1 and T-NP<sub>si</sub>sFLT1 nanoparticles were proved to be stable in PBS and shown strong ability in the protection of encapsulated siRNA. HTR-8/SVneo cells were generated from isolated first trimester extravillous cytotrophoblasts through the infection with simian virus 40 large T antigen (Abou-Kheir et al., 2017). In human trophoblast HTR-8/SVneo cells, the existence of P-CSA-BP on the surface of nanoparticles significantly enhanced its accumulation ability, which was shown by both flow cytometry analyses and immunofluorescence results. We also checked the efficiency of NP<sub>si</sub>sFLT1 and T-NP<sub>si</sub>sFLT1 nanoparticles in targeting to the placentas of pregnant CD1 mice. Ex vivo images and HPLC results demonstrated that nanoparticles with P-CSA-BP on the surface had a significantly stronger accumulation in the placenta of mice. So, conjugating P-CSA-BP to the surface of PEG-PLA nanoparticles enhanced its ability in targeted delivery of drugs to the placenta.

In this research, we aimed to decrease the expression of sFLT1 in placenta through the trophoblast-targeted nanoparticles encapsulating sFLT1 siRNA. In HTR-8/SVneo cells, T-NP<sub>si</sub>sFLT1 nanoparticles had a higher efficiency in inhibition of sFLT1 expression than NP<sub>si</sub>sFLT1 nanoparticles, which was shown in both mRNA and protein levels. Also, after being injected into pregnant CD1 mice, T-NP<sub>si</sub>sFLT1 nanoparticles significantly decreased the sFLT1 mRNA level in placenta and sFLT1 protein level in serum. Trophoblast-targeted sFLT1 siRNA-encapsulated T-NP<sub>si</sub>sFLT1 nanoparticles had a strong ability in the inhibition of sFLT1 expression in placenta and decreasing the amount of sFLT1 in circulation.

Nanoparticles used as delivery system in the therapy of PE must be safe for both mother and fetus. It should have no adverse effects on tissues, do not cross the placenta into fetus, and show no apparent fetal toxicity. The injection of T-NP<sub>si</sub>sFLT1 nanoparticles did not influenced the enzyme activities of ALT and AST in pregnant mice. Meanwhile, the newborn pups number and weights were also not changed. These results illustrated that the utility of T-NP<sub>si</sub>sFLT1 nanoparticles as a sFLT1 siRNA placenta specific delivery system was safe in mice.

In order for this placenta targeted nanoparticles to be adopted and accepted clinically, further research and development are required. The maximum dosage of this nanoparticles should be tested. The nanoparticles should be optimized to improve the efficiency in encapsulating and releasing sFLT1 siRNA. More toxicity tests should be performed in different animal models to ensure the safety of this nanoparticles. Although we had demonstrated sFLT1 silencing function of T-NP<sub>si</sub>sFLT1 nanoparticles in mouse placenta, but its effects in the prevention or therapy against PE in mice was not investigated. So,
further studies should be done to demonstrate the function of T-NPsisFLT1 nanoparticles in PE therapy. In conclusion, the employment of T-NPsisFLT1 nanoparticles as a sFLT1 siRNA placenta specific delivery system significantly silenced sFLT1 in mice and was safe for both the mother and fetus. This nanoparticle might serve as a novel potential therapeutic strategy for PE.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

**ETHICS STATEMENT**

The animal study was reviewed and approved by the Shandong Provincial Hospital Affiliated to Shandong University.

**REFERENCES**

Abou-Kheir, W., Barrak, J., Hadadeh, O., and Daoud, G. (2017). HTR-8/SVneo cell line contains a mixed population of cells. Placenta 50, 1–7. doi: 10.1016/j.placenta.2016.12.007

Ahmad, S., and Ahmed, A. (2004). Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 95, 884–891. doi: 10.1161/01.RES.0000147365.86159.F5

Ahmed, A., Rezai, H., and Broadway-Stringer, S. (2017). Evidence-based revised Provincial Hospital Affiliated to Shandong University.

**AUTHOR CONTRIBUTIONS**

LL, HY, and PC conceived the study. TX, QZ, DW, and YZ designed the experiments and analyzed the data. SW secured the funding and supervised the project.

**FUNDING**

This study was supported by the Key Research & Development Project of Shandong Province (2019GSF108096), the National Natural Science Foundation of China (81801473, 81971409, 81741037, 81741038, and 81100447), the Shandong Medical and Health Technology Development Program of China (2016WS0412), the Chongqing Postdoctoral Research Special Funding Project (XmT2018077), the China Postdoctoral Science Foundation (2018M631067 and 2019T120814), the Open Project of NHC Key Laboratory of Fertility Control Technology (2018KF002), and the Jinan Science and Technology Program (201907011 and 201907012).

**FUNDING**

This study was supported by the Key Research & Development Project of Shandong Province (2019GSF108096), the National Natural Science Foundation of China (81801473, 81971409, 81741037, 81741038, and 81100447), the Shandong Medical and Health Technology Development Program of China (2016WS0412), the Chongqing Postdoctoral Research Special Funding Project (XmT2018077), the China Postdoctoral Science Foundation (2018M631067 and 2019T120814), the Open Project of NHC Key Laboratory of Fertility Control Technology (2018KF002), and the Jinan Science and Technology Program (201907011 and 201907012).
Thadhani, R., Hagmann, H., Schaarschmidt, W., Roth, B., Cingoez, T., Karumanchi, S. A., et al. (2016). Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. *J. Am. Soc. Nephrol.* 27, 903–913. doi: 10.1681/ASN.2015020157

Turanov, A. A., Lo, A., Hassler, M. R., Makris, A., Ashar-Patel, A., Alterman, J. F., et al. (2018). RNAi modulation of placental sFLT1 for the treatment of preeclampsia. *Nat. Biotechnol.* 36, 1164–1173. doi: 10.1038/nbt.4297

von Dadelszen, P., and Magee, L. A. (2014). Pre-eclampsia: an update. *Curr. Hypertens. Rep.* 16:454. doi: 10.1007/s11906-014-0454-8

World Health Organization [WHO] (2011). *WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia*. Geneva: WHO Guidelines Approved by the Guidelines Review Committee.

Xu, C. F., Zhang, H. B., Sun, C. Y., Liu, Y., Shen, S., Yang, X. Z., et al. (2016). Tumor acidity-sensitive linkage-bridged block copolymer for therapeutic siRNA delivery. *Biomaterials* 88, 48–59. doi: 10.1016/j.biomaterials.2016.02.031

Yang, X. Z., Dou, S., Sun, T. M., Mao, C. Q., Wang, H. X., and Wang, J. (2011). Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. *J. Control Release* 156, 203–211. doi: 10.1016/j.jconrel.2011.07.035

Yu, J., Jia, J., Guo, X., Chen, R., and Feng, L. (2017). Modulating circulating sFlt1 in an animal model of preeclampsia using PAMAM nanoparticles for siRNA delivery. *Placenta* 58, 1–8. doi: 10.1016/j.placenta.2017.07.360

Zhang, B., Tan, L., Yu, Y., Wang, B., Chen, Z., Han, J., et al. (2018). Placenta-specific drug delivery by trophoblast-targeted nanoparticles in mice. *Theranostics* 8, 2765–2781. doi: 10.7150/thno.22904

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2020 Li, Yang, Chen, Xin, Zhou, Wei, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**